Imaging prostate cancer lymph node metastases with a multimodality contrast agent

Methods to detect lymph node (LN) metastases in prostate cancer (PCa) are limited. Pelvic LN dissection is commonly performed during prostatectomy, but often followed by morbid complications. More refined methods for detecting LN invasion are needed.

[1]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[2]  Kai Chen,et al.  Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Ryan Park,et al.  microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  S. Greenfield,et al.  Overtreatment of men with low‐risk prostate cancer and significant comorbidity , 2011, Cancer.

[5]  Martin G Pomper,et al.  68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. , 2010, Journal of medicinal chemistry.

[6]  H. Moch,et al.  Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. , 2006, Gynecologic oncology.

[7]  D. Grignon,et al.  Elevated expression of cancer‐associated proliferating cell nuclear antigen in high‐grade prostatic intraepithelial neoplasia and prostate cancer , 2011, The Prostate.

[8]  Shi Ke,et al.  A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. , 2007, Bioconjugate chemistry.

[9]  Jennifer R. Brown,et al.  Preclinical assessment of an anti-EpCAM immunotoxin: locoregional delivery provides a safer alternative to systemic administration. , 2009, Cancer biotherapy & radiopharmaceuticals.

[10]  M. Steurer,et al.  Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance , 2006, Journal of Clinical Pathology.

[11]  Eva M. Sevick-Muraca,et al.  Single-Dose Intravenous Toxicity Study of IRDye 800CW in Sprague-Dawley Rats , 2010, Molecular Imaging and Biology.

[12]  P. Low,et al.  Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. , 2009, Molecular pharmaceutics.

[13]  R. Price,et al.  Detection of Cancer Metastases with a Dual-labeled Near-Infrared/Positron Emission Tomography Imaging Agent. , 2010, Translational oncology.

[14]  F. Wawroschek,et al.  The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. , 2003, European urology.

[15]  Philip S Low,et al.  Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. , 2009, Molecular pharmaceutics.

[16]  C. Gondi,et al.  RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. , 2006, The Journal of biological chemistry.

[17]  H. Koprowski,et al.  Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. , 1984, Journal of biological response modifiers.

[18]  A. Fenster,et al.  Molecular Targeted Enhanced Ultrasound Imaging of Flk1 Reveals Diagnosis and Prognosis Potential in a Genetically Engineered Mouse Prostate Cancer Model , 2009, Molecular imaging.

[19]  H. Daldrup-Link,et al.  Optical Imaging of Cellular Immunotherapy against Prostate Cancer , 2009, Molecular imaging.

[20]  H. Koprowski,et al.  PHASE-I CLINICAL TRIAL OF MONOCLONAL ANTIBODY IN TREATMENT OF GASTROINTESTINAL TUMOURS , 1982, The Lancet.

[21]  A. Heidenreich,et al.  Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.

[22]  M Vasei,et al.  Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers , 2006, British Journal of Cancer.

[23]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[24]  E. Bergstralh,et al.  Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. , 2007, The Journal of urology.

[25]  S. Asbell,et al.  Surgical staging in carcinoma of the prostate: The RTOG experience , 1985, The Prostate.

[26]  G. Sauter,et al.  High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer , 2004, Breast Cancer Research and Treatment.

[27]  G. Holl,et al.  Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  Eva M. Sevick-Muraca,et al.  Dual-Labeled Trastuzumab-Based Imaging Agent for the Detection of Human Epidermal Growth Factor Receptor 2 Overexpression in Breast Cancer , 2007, Journal of Nuclear Medicine.

[29]  W. Cai,et al.  In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin αvβ3 , 2006 .

[30]  M. Ross,et al.  Lymphedema beyond breast cancer , 2010, Cancer.

[31]  U. Roggenbuck,et al.  Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006. , 2008, The Journal of urology.

[32]  Anke M Hövels,et al.  Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. , 2009, Radiology.

[33]  A. Wu,et al.  Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen–Expressing Tumors , 2008, Clinical Cancer Research.

[34]  Meng Yang,et al.  Real‐time whole‐body imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein , 2005, The Prostate.

[35]  F. Montorsi,et al.  Pelvic lymph node dissection in prostate cancer. , 2009, European urology.

[36]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[37]  P. Waldenberger,et al.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. , 2010, Radiology.

[38]  F. Fazio,et al.  Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. , 2009, European urology.

[39]  A. Wu,et al.  Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. , 2008, Protein engineering, design & selection : PEDS.

[40]  M. Emmert-Buck,et al.  Identification of EpCAM as a molecular target of prostate cancer stroma. , 2009, The American journal of pathology.

[41]  W. Strohl,et al.  Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays. , 2007, Journal of immunological methods.

[42]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[43]  Sanjiv S. Gambhir,et al.  Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature , 2007, Journal of Nuclear Medicine.

[44]  J. Hsieh,et al.  A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection , 2011, Amino Acids.

[45]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[46]  O. Gires,et al.  EpCAM (CD326) finding its role in cancer , 2007, British Journal of Cancer.

[47]  A. Haese*,et al.  The presence of prostate cancer on saturation biopsy can be accurately predicted , 2010, BJU international.

[48]  Guenter Janetschek,et al.  Papel de la biopsia dinámica del ganglio centinela en el cáncer de próstata organoconfinado , 2007 .

[49]  Martin G Pomper,et al.  A low molecular weight PSMA-based fluorescent imaging agent for cancer. , 2009, Biochemical and biophysical research communications.

[50]  M. Ittmann,et al.  Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. , 2001, Cancer research.

[51]  H. Miyake,et al.  Quantitative Detection of Micrometastases in Pelvic Lymph Nodes in Patients with Clinically Localized Prostate Cancer by Real-time Reverse Transcriptase-PCR , 2007, Clinical Cancer Research.

[52]  P. Choyke,et al.  PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. , 2011, Seminars in nuclear medicine.

[53]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[54]  H. Hricak,et al.  Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. , 2007, Radiology.

[55]  H. Miyake,et al.  Significance of micrometastases in prostate cancer. , 2008, Surgical oncology.

[56]  P Tsipouras,et al.  Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope , 2008, British Journal of Cancer.

[57]  J. Seidel,et al.  N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer , 2008, Clinical Cancer Research.

[58]  A. Koong,et al.  Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[59]  A. Luebke,et al.  Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker , 2006, BMC Cancer.

[60]  Stephen J Mather,et al.  Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes , 2006, Nature Protocols.

[61]  A. Haese*,et al.  [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study. , 2010, European journal of cancer.

[62]  M. Gertsenstein,et al.  Mouse in red: Red fluorescent protein expression in mouse ES cells, embryos, and adult animals , 2004, Genesis.

[63]  B. Rice,et al.  Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models. , 2004, Molecular imaging.

[64]  Milton V. Marshall,et al.  Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study. , 2008, Radiology.

[65]  B. Wollenberg,et al.  Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody. , 2007, Anticancer research.

[66]  A. Heidenreich,et al.  Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. , 2007, European urology.

[67]  Martin G Pomper,et al.  Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). , 2008, Journal of medicinal chemistry.

[68]  Eun Kyoung Ryu,et al.  18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging , 2008, Journal of Nuclear Medicine.

[69]  Shi Ke,et al.  Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe. , 2005, Journal of biomedical optics.

[70]  B. Delahunt,et al.  International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes , 2011, Modern Pathology.

[71]  W. Bodmer,et al.  USE OF TWO EPITHELIUM-SPECIFIC MONOCLONAL ANTIBODIES FOR DIAGNOSIS OF MALIGNANCY IN SEROUS EFFUSIONS , 1982, The Lancet.

[72]  M. Herlyn,et al.  Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Hao Hong,et al.  Positron emission tomography imaging of prostate cancer , 2010, Amino Acids.